Skip to content

3 penny stocks to buy under $1 in September

3 penny stocks to buy under $1 in September
Kliment Dukovski

Due to its low price, penny stocks may seem like a good place to invest your money. But they come with high risk. Depending on the company, especially if it’s traded over-the-counter (OTC) it may be hard to find accurate financial information.

Another issue you may face is liquidity. If you want to purchase a large number of shares, you may find it hard to do so without pushing the price higher.

However, if you find the right penny stock, you could be greatly rewarded.

Avalo Therapeutics, Inc. (NASDAQ: AVTX)

Avalo Therapeutics, Inc. is a clinical-stage biotech company focused on the treatment of immune dysregulation. One of its products, called AVTX-002, is an anti-light monoclonal antibody treatment for non-eosinophilic asthma, Crohn’s disease, and COVID-19.

The company recently announced an asset sale of its rights, title, and interest in assets that are part of the AVTX-800 series to AUG Therapeutics. The company will get a $150,000 upfront payment and up to $15 million for each compound milestone.

Morningstar’s quantitative equity report gives AVTX a fair value of $0.18, which is 18% below the current price of $0.22.

Morningstar quantitative equity report for the AVTX stock. Source: Interactive Brokers Fundamentals Explorer

Affimed (NASDAQ: AFMD)

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. Its products are developed in the field of immuno-oncology.

On September 12, the company received a fast-track designation for an experimental therapy of Hodking lymphoma by the US Food and Drug Administration (FDA).

That said, Morningstar’s analyst equity report gives a 119% higher fair value of $1.14 per share, than AFMD’s market price of $0.52.

Morningstar analyst equity report on the AFMD stock. Source: Interactive Brokers Fundamentals Explorer

ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA)

Immersion Corp is a clinical-stage biopharmaceutical company focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. 

The company received an upgrade from analyst firm H.C. Wainwright on September 8, with a ‘buy’ rating and a target price of $2.50.

ZyVersa has been given a fair value of $0.31 by Morningstar’s analyst equity report. That’s 63% higher than ZVSA’s market price of $0.19 per share.

Morningstar analyst equity report on the ZVSA stock. Source: Interactive Brokers Fundamentals Explorer

S&P 500’s 16% return year-to-date has outperformed all three stocks. ZVSA is down 89%, AFMD is down 57% and AVTX is down 95% during the same period.

Buy stocks now with Interactive Brokers – the most advanced investment platform

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in 70+ cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. eToro USA LLC does not offer CFDs, only real Crypto assets available. Don’t invest unless you’re prepared to lose all the money you invest.

Read Next:

Weekly Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.